Thompson Siegel & Walmsley LLC Abb Vie Inc. Transaction History

Thompson Siegel & Walmsley LLC

$6.71 Billion
Q3 2024

A detailed history of Thompson Siegel & Walmsley LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Thompson Siegel & Walmsley LLC holds 73,339 shares of ABBV stock, worth $12.4 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares

73,339

Previous 72,629 0.98%

Holding current value

$12.4 Million

Previous $12.5 Million 16.26%

% of portfolio

0.22%

Previous 0.2%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$163.84 - $199.33 $116,326 - $141,524	710 Added 0.98%	73,339 $14.5 Million
Q2 2024 Aug 08, 2024	BUY	$154.79 - $180.76 $6,036 - $7,049	39 Added 0.05%	72,629 $12.5 Million
Q1 2024 May 09, 2024	SELL	$159.82 - $182.1 $11,986 - $13,657	-75 Reduced 0.1%	72,590 $13.2 Million
Q4 2023 Feb 07, 2024	SELL	$137.6 - $154.97 $5,504 - $6,198	-40 Reduced 0.06%	72,665 $11.3 Million
Q3 2023 Nov 08, 2023	SELL	$133.59 - $154.65 $4,007 - $4,639	-30 Reduced 0.04%	72,705 $10.8 Million
Q1 2023 May 11, 2023	SELL	$144.61 - $166.54 $867 - $999	-6 Reduced 0.01%	72,735 $11.6 Million
Q4 2022 Feb 10, 2023	SELL	$138.31 - $165.87 $105,945 - $127,056	-766 Reduced 1.04%	72,741 $11.8 Million
Q3 2022 Dec 15, 2022	BUY	$134.21 - $153.93 $9.87 Million - $11.3 Million	73,507 New	73,507 $9.87 Million
Q2 2022 Jul 22, 2022	SELL	$137.62 - $174.96 $886,823 - $1.13 Million	-6,444 Reduced 6.25%	96,657 $14.8 Million
Q1 2022 Apr 26, 2022	SELL	$131.98 - $163.75 $3,431 - $4,257	-26 Reduced 0.03%	103,101 $16.7 Million
Q4 2021 Feb 09, 2022	BUY	$107.43 - $135.93 $1.88 Million - $2.38 Million	17,500 Added 20.44%	103,127 $14 Million
Q3 2021 Nov 05, 2021	BUY	$106.4 - $120.78 $758,100 - $860,557	7,125 Added 9.08%	85,627 $9.24 Million
Q2 2021 Aug 09, 2021	SELL	$105.21 - $117.21 $150,660 - $167,844	-1,432 Reduced 1.79%	78,502 $8.84 Million
Q1 2021 May 07, 2021	SELL	$102.3 - $112.62 $89,819 - $98,880	-878 Reduced 1.09%	79,934 $8.65 Million
Q4 2020 Feb 08, 2021	SELL	$80.49 - $108.67 $195,832 - $264,394	-2,433 Reduced 2.92%	80,812 $8.66 Million
Q3 2020 Nov 12, 2020	SELL	$85.91 - $100.83 $2.49 Million - $2.92 Million	-28,942 Reduced 25.8%	83,245 $7.29 Million
Q2 2020 Aug 11, 2020	BUY	$73.37 - $98.18 $2.64 Million - $3.53 Million	35,956 Added 47.17%	112,187 $11 Million
Q1 2020 May 12, 2020	BUY	$64.5 - $97.79 $1.65 Million - $2.5 Million	25,517 Added 50.32%	76,231 $5.81 Million
Q4 2019 Feb 07, 2020	BUY	$72.13 - $90.25 $1.12 Million - $1.4 Million	15,491 Added 43.98%	50,714 $4.49 Million
Q3 2019 Nov 12, 2019	BUY	$62.98 - $75.72 $245,999 - $295,762	3,906 Added 12.47%	35,223 $2.67 Million
Q2 2019 Aug 12, 2019	BUY	$65.7 - $83.98 $54,399 - $69,535	828 Added 2.72%	31,317 $2.28 Million
Q1 2019 May 13, 2019	SELL	$77.14 - $90.79 $1.5 Million - $1.76 Million	-19,422 Reduced 38.91%	30,489 $2.46 Million
Q4 2018 Feb 11, 2019	SELL	$77.85 - $96.01 $467,099 - $576,060	-6,000 Reduced 10.73%	49,911 $4.6 Million
Q3 2018 Nov 08, 2018	SELL	$88.91 - $98.84 $15,559 - $17,297	-175 Reduced 0.31%	55,911 $5.29 Million
Q2 2018 Aug 09, 2018	BUY	$89.78 - $106.23 $49,379 - $58,426	550 Added 0.99%	56,086 $5.2 Million
Q1 2018 May 08, 2018	SELL	$92.01 - $123.21 $423,246 - $566,766	-4,600 Reduced 7.65%	55,536 $5.26 Million
Q4 2017 Feb 09, 2018	BUY	$89.56 - $98.21 $165,327 - $181,295	1,846 Added 3.17%	60,136 $5.82 Million
Q3 2017 Nov 08, 2017	SELL	$69.85 - $89.22 $705,973 - $901,746	-10,107 Reduced 14.78%	58,290 $5.18 Million
Q2 2017 Aug 09, 2017	BUY	N/A	68,397	68,397 $4.96 Million

Others Institutions Holding ABBV

# of Institutions

3,837

Shares Held

1.25B

Call Options Held

15.7M

Put Options Held

11.3M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $300B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Thompson Siegel & Walmsley LLC, based on Form 13F filings with the SEC.

News

Stay updated on Thompson Siegel & Walmsley LLC with notifications on news.

Account

Thompson Siegel & Walmsley LLC Abb Vie Inc. Transaction History